Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns –
– Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been initiated –
Related news for (EVLO)
- Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
- Evelo Biosciences Closes $25.5 Million Private Placement
- Evelo Biosciences Announces $25.5 Million Private Placement